In Part A, the columns for chlorantraniliprole, dicamba, difenoconazole, glufosinate-ammonium, imazapic, imazapyr, mandipropamid, penthiopyrad and spirotetramat are replaced by the following:
Groupes et exemples de produits individuels auxquels s’appliquent les LMR [6]